Determination of the frequency of carbapenem resistance among Acinetobacter baumannii isolates obtained from hospitalized patients in Ghaem and Imam Reza hospitals

Document Type : Original article

Authors

1 Professor, Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Assistant Professor, Department of Microbiology and Virology, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran

10.22038/nnj.2026.90712.1510

Abstract

Background and Aims: Acinetobacter baumannii is one of the most important nosocomial opportunistic pathogens, which is considered the cause of many infections. In recent years, the resistance of this bacterium to carbapenems has intensified concerns around the world. This study aimed to determine the frequency pattern and the trend of changes in resistance to carbapenems in clinical isolates of Acinetobacter baumannii in Ghaem and Imam Reza hospitals of Mashhad.
Materials and Methods: During three years (1396 to 1398), 3581 isolates of Acinetobacter baumannii were collected by culturing non-repeated samples of patients hospitalized in different departments of Qaim and Imam Reza hospitals. After the identification and final confirmation of the bacteria, the level of resistance to carbapenems was evaluated by the Kirby-Bauer standard method and the trend of resistance changes was also investigated.
Results: The highest number of Acinetobacter baumannii isolates were isolated from intensive care units (38/33%), surgery (20/88%), and emergency departments (20/4%). The rate of resistance to amikacin was 85.06%, ciprofloxacin 90.89%, imipenem 84.94%, meropenem 88.57%, and colisitin 18.3%. The trend of changes in resistance to carbapenems in Qaim Hospital was associated with a slight decrease, while in Imam Reza Hospital, the state of resistance remained stable and stable.
Conclusion: Considering the significant resistance to carbapenems, it is considered essential to perform antimicrobial sensitivity tests before selecting and prescribing the appropriate antibiotic.

Keywords

References

[1] McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS microbiology reviews. 2013;37(2):130-55.
 [2] Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clinical microbiology reviews. 2008;21(3):538-82.
 [3] Gedefie A, Demsis W, Ashagrie M, Kassa Y, Tesfaye M, Tilahun M, Bisetegn H, Sahle Z, et al. Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: a review. Infection and drug resistance. 2021:3711-9.
 [4] Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens. 2021;10(3):373.
 [5] Nowak P, Paluchowska P. Acinetobacter baumannii: biology and drug resistance—role of carbapenemases. Folia histochemica et cytobiologica. 2016;54(2):61-74.
 [6] Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, Muleiro Álvarez M, Vega López EN, Franyuti-Kelly G, Álvarez-Hernández DA, Moncaleano Guzmán V, et al. Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics. 2020;9(4):205.
 [7] Moradi J, Hashemi FB, Bahador A. Antibiotic resistance of Acinetobacter baumannii in Iran: a systemic review of the published literature. Osong public health and research perspectives. 2015;6(2):79-86.
 [8] Keikha M, Karbalaei M, Rahimi F, Abadi AT. The prevalence of antibiotic-resistant Acinetobacter baumannii infections among the Iranian ICU patients: A systematic review and meta-analysis. Gene Reports. 2023;30:101731.
 [9] Rahimzadeh G, Rezai MS, Farshidi F. Genotypic patterns of multidrug-resistant Acinetobacter baumannii: A systematic review. Advanced Biomedical Research. 2023;12(1):56.
 [10] Cain AK, Hamidian M. Portrait of a killer: Uncovering resistance mechanisms and global spread of Acinetobacter baumannii. PLoS Pathogens. 2023;19(8):e1011520.
 [11] Wu HJ, Xiao ZG, Lv XJ, Huang HT, Liao C, Hui CY, Xu Y, Li HF, et al. Drug‑resistant Acinetobacterábaumannii: From molecular mechanisms to potential therapeutics. Experimental and therapeutic medicine. 2023;25(5):1-0.
 [12] Tavasol A, Khademolhosseini S, Noormohamad M, Ghasemi M, Mahram H, Salimi M, Fathi M, Sardaripour A, Zangi M, et al. Worldwide Prevalence of Carbapenem Resistance in Acinetobacter baumannii: A Systematic Review and Meta-analysis. Infectious Diseases in Clinical Practice. 2023;31(2):e1236.
 [13] Howard A, O’Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012;3(3):243-50.
 [14] Novović K, Jovčić B. Colistin resistance in Acinetobacter baumannii: molecular mechanisms and epidemiology. Antibiotics. 2023;12(3):516.
 [15] Pormohammad A, Mehdinejadiani K, Gholizadeh P, Nasiri MJ, Mohtavinejad N, Dadashi M, Karimaei S, Safari H, Azimi T, et al. Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: A systematic review and meta-analysis. Microbial pathogenesis. 2020;139:103887.
 [16] Shin JA, Chang YS, Kim HJ, Kim SK, Chang J, Ahn CM, Byun MK, et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection. Yonsei medical journal. 2012;53(5):974.
 [17] Keikha M, Kamali H, Ghazvini K, Karbalaei M. Conceptual framework of antibiotic stewardship programs in reducing ESBL-producing Enterobacteriaceae: a systematic review and meta-analysis. Journal of Chemotherapy. 2022;34(8):483-91.
 [18] Humphries RM, Kircher S, Ferrell A, Krause KM, Malherbe R, Hsiung A, Burnham CA, et al. The continued value of disk diffusion for assessing antimicrobial susceptibility in clinical laboratories: report from the clinical and laboratory standards institute methods development and standardization working group. Journal of clinical microbiology. 2018;56(8):10-128.
 [19] Azimi L, Talebi M, Pourshafie MR, Owlia P, Lari AR. Characterization of carbapenemases in extensively drug resistance Acinetobacter baumannii in a burn care center in Iran. International journal of molecular and cellular medicine. 2015;4(1):46.
 [20] Ibrahim S, Al-Saryi N, Al-Kadmy IM, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Molecular biology reports. 2021;48(10):6987-98.
 [21] Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, Muleiro Álvarez M, Vega López EN, Franyuti-Kelly G, Álvarez-Hernández DA, Moncaleano Guzmán V, et al. Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics. 2020;9(4):205.
 [22] Rodriguez CH, Brune A, Nastro M, Vay C, Famiglietti A. In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. Journal of Medical Microbiology. 2020;69(7):928-31.
 [23] Karakonstantis S. A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii. Journal of Chemotherapy. 2020;33(1):1-1.
 [24] Karbasizade V, Heidari L. Antimicrobial resistance of Acinetobacter baumannii isolated from Intensive Care Units of Isfahan hospitals, Iran. Journal of Isfahan Medical School. 2012;30(191).
 [25] Zahra N, Zeshan B, Qadri MM, Ishaq M, Afzal M, Ahmed N, et al. Phenotypic and genotypic evaluation of antibiotic resistance of Acinetobacter baumannii bacteria isolated from surgical intensive care unit patients in Pakistan. Jundishapur Journal of Microbiology. 2021;14(4).
 [26] Şimşek M, Demir C. Determination of colistin and tigecycline resistance profile of Acinetobacter baumannii strains from different clinical samples in a territory hospital in Turkey. 2020.
 [27] Lemos EV, de La Hoz FP, Einarson TR, McGhan WF, Quevedo E, Castañeda C, Kawai K, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clinical Microbiology and Infection. 2014;20(5):416-23.
 [28] Lima WG, Alves GC, Sanches C, Fernandes SO, de Paiva MC. Carbapenem-resistant Acinetobacter baumannii in patients with burn injury: A systematic review and meta-analysis. Burns. 2019;45(7):1495-508.
 [29] Beigverdi R, Sattari-Maraji A, Emaneini M, Jabalameli F. Status of carbapenem-resistant Acinetobacter baumannii harboring carbapenemase: First systematic review and meta-analysis from Iran. Infection, Genetics and Evolution. 2019;73:433-43.
 [30] Hashemizadeh Z, Emami A, Rahimi MJ. Acinetobacter antibiotic resistance and frequency of ESBL-producing strains in ICU patients of Namazi Hospital (2008-2009). Journal of Inflammatory Diseases. 2010;14(2):47-53.
 [31] Japoni-Nejad A, Sofian M, van Belkum A, Ghaznavi-Rad E. Nosocomial outbreak of extensively and pan drug-resistant Acinetobacter baumannii in tertiary hospital in central part of Iran. Jundishapur Journal of microbiology. 2013;6(8).
 [32] Karbalaei M, Keikha M. Antimicrobial stewardship for surgeons; the urgent need for new directions–Correspondence. International Journal of Surgery. 2022;104:106758.
 [33] Bostanghadiri N, Narimisa N, Mirshekar M, Dadgar-Zankbar L, Taki E, Navidifar T, Darban-Sarokhalil D, et al. Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Antimicrobial Resistance & Infection Control. 2024;13(1):24.
 [34] Pormohammad A, Mehdinejadiani K, Gholizadeh P, Nasiri MJ, Mohtavinejad N, Dadashi M, Karimaei S, Safari H, Azimi T, et al. Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: A systematic review and meta-analysis. Microbial pathogenesis. 2020;139:103887.
 [35] Bostanghadiri N, Narimisa N, Mirshekar M, Dadgar-Zankbar L, Taki E, Navidifar T, Darban-Sarokhalil D, et al. Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Antimicrobial Resistance & Infection Control. 2024;13(1):24.
Navid No
Volume 28, Issue 96
March 2026
Pages 38-51

Files

Share

How to cite

Statistics